Ahmad A Abdul-Aziz1, Rodney A Hayward2, Keith D Aaronson1, Scott L Hummel3. 1. University of Michigan Health System, Ann Arbor. 2. Ann Arbor Veterans Affairs Health System, Ann Arbor, Michigan. 3. University of Michigan Health System, Ann Arbor2Ann Arbor Veterans Affairs Health System, Ann Arbor, Michigan.
Abstract
Importance: US hospitals receive financial penalties for excess risk-standardized 30-day readmissions and mortality in Medicare patients. Under current policy, readmission prevention is incentivized over 10-fold more than mortality reduction. Objective: To determine how penalties for US hospitals would change if policy equally weighted 30-day readmissions and mortality. Design, Setting, and Participants: Publicly available hospital-level data for fiscal year 2014 was obtained, including excess readmission ratio (ERR; risk-standardized predicted over expected 30-day readmissions) and 30-day mortality rates for heart failure, pneumonia, and acute myocardial infarction, as well as readmission penalties (as percent of Medicare Diagnosis Group payments). An excess mortality ratio (EMR) was calculated by dividing the risk-standardized predicted mortality by the national average mortality. Case-weighted aggregate ERR (ERRAGG) and EMR (EMRAGG) were calculated, and an excess combined outcome ratio (ECORAGG) was created by averaging ERRAGG and EMRAGG. We examined associations between readmission penalties, ERRAGG, EMRAGG, and ECORAGG. Analysis of variance was used to compare readmission penalties in hospitals with concordant (both ratios >1 or <1) and discordant performance by ERRAGG and ECORAGG. Main Outcomes and Measures: The primary outcome investigated was the association between readmission penalties and the calculated excess combined outcome ratio (ECORAGG). Results: In 1963 US hospitals with complete data, readmission penalties closely tracked excess readmissions (r = 0.81; P < .001), but were minimally and inversely related with excess mortality (r = -0.12; P < .001) and only modestly correlated with excess combined readmission and mortality (r = 0.36; P < .001). Using hospitals with concordant ERRAGG and ECORAGG as the reference group, 17% of hospitals had an ECORAGG ratio less than 1 (ie, superior combined mortality/readmission outcome) with an ERRAGG ratio greater than 1, and received higher mean (SD) readmission penalties (0.41% [0.28%] vs 0.29% [0.37%]; P < .001); 16% of US hospitals had an ECORAGG ratio of greater than 1 (ie, inferior combined mortality/readmission outcome) with an ERRAGG ratio less than 1, and received minimal mean (SD) readmission penalties (0.08% [0.12%]; P < .001 for comparison with reference). Conclusions and Relevance: In fiscal year 2014, financial penalties for one-third of US hospitals would have been substantially altered if 30-day readmission and mortality were considered equally important. Under most circumstances, patients would rather avoid death than rehospitalization. Current Medicare financial penalties do not meet the goals of aligning incentives and fairly reimbursing hospitals for patient-centered outcomes.
Importance: US hospitals receive financial penalties for excess risk-standardized 30-day readmissions and mortality in Medicare patients. Under current policy, readmission prevention is incentivized over 10-fold more than mortality reduction. Objective: To determine how penalties for US hospitals would change if policy equally weighted 30-day readmissions and mortality. Design, Setting, and Participants: Publicly available hospital-level data for fiscal year 2014 was obtained, including excess readmission ratio (ERR; risk-standardized predicted over expected 30-day readmissions) and 30-day mortality rates for heart failure, pneumonia, and acute myocardial infarction, as well as readmission penalties (as percent of Medicare Diagnosis Group payments). An excess mortality ratio (EMR) was calculated by dividing the risk-standardized predicted mortality by the national average mortality. Case-weighted aggregate ERR (ERRAGG) and EMR (EMRAGG) were calculated, and an excess combined outcome ratio (ECORAGG) was created by averaging ERRAGG and EMRAGG. We examined associations between readmission penalties, ERRAGG, EMRAGG, and ECORAGG. Analysis of variance was used to compare readmission penalties in hospitals with concordant (both ratios >1 or <1) and discordant performance by ERRAGG and ECORAGG. Main Outcomes and Measures: The primary outcome investigated was the association between readmission penalties and the calculated excess combined outcome ratio (ECORAGG). Results: In 1963 US hospitals with complete data, readmission penalties closely tracked excess readmissions (r = 0.81; P < .001), but were minimally and inversely related with excess mortality (r = -0.12; P < .001) and only modestly correlated with excess combined readmission and mortality (r = 0.36; P < .001). Using hospitals with concordant ERRAGG and ECORAGG as the reference group, 17% of hospitals had an ECORAGG ratio less than 1 (ie, superior combined mortality/readmission outcome) with an ERRAGG ratio greater than 1, and received higher mean (SD) readmission penalties (0.41% [0.28%] vs 0.29% [0.37%]; P < .001); 16% of US hospitals had an ECORAGG ratio of greater than 1 (ie, inferior combined mortality/readmission outcome) with an ERRAGG ratio less than 1, and received minimal mean (SD) readmission penalties (0.08% [0.12%]; P < .001 for comparison with reference). Conclusions and Relevance: In fiscal year 2014, financial penalties for one-third of US hospitals would have been substantially altered if 30-day readmission and mortality were considered equally important. Under most circumstances, patients would rather avoid death than rehospitalization. Current Medicare financial penalties do not meet the goals of aligning incentives and fairly reimbursing hospitals for patient-centered outcomes.
Authors: Elizabeth H Bradley; Leslie Curry; Leora I Horwitz; Heather Sipsma; Jennifer W Thompson; MaryAnne Elma; Mary Norine Walsh; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2012-07-18 Impact factor: 24.094
Authors: Gregg C Fonarow; Mark J Alberts; Joseph P Broderick; Edward C Jauch; Dawn O Kleindorfer; Jeffrey L Saver; Penelope Solis; Robert Suter; Lee H Schwamm Journal: Stroke Date: 2014-02-12 Impact factor: 7.914
Authors: Harlan M Krumholz; Zhenqiu Lin; Patricia S Keenan; Jersey Chen; Joseph S Ross; Elizabeth E Drye; Susannah M Bernheim; Yun Wang; Elizabeth H Bradley; Lein F Han; Sharon-Lise T Normand Journal: JAMA Date: 2013-02-13 Impact factor: 56.272
Authors: Alexander Göhler; Benjamin P Geisler; Jennifer M Manne; Mikhail Kosiborod; Zefeng Zhang; William S Weintraub; John A Spertus; G Scott Gazelle; Uwe Siebert; David J Cohen Journal: Value Health Date: 2008-07-18 Impact factor: 5.725
Authors: Marc D Samsky; Andrew P Ambrosy; Erik Youngson; Li Liang; Padma Kaul; Adrian F Hernandez; Eric D Peterson; Finlay A McAlister Journal: JAMA Cardiol Date: 2019-05-01 Impact factor: 14.676
Authors: Kimon L H Ioannides; Avi Baehr; David N Karp; Douglas J Wiebe; Brendan G Carr; Daniel N Holena; M Kit Delgado Journal: Acad Emerg Med Date: 2018-05-31 Impact factor: 3.451
Authors: Muthiah Vaduganathan; Cian P McCarthy; Colby Ayers; Deepak L Bhatt; Dharam J Kumbhani; James A de Lemos; Gregg C Fonarow; Ambarish Pandey Journal: Eur Heart J Qual Care Clin Outcomes Date: 2020-01-01
Authors: Ben J Marafino; Alejandro Schuler; Vincent X Liu; Gabriel J Escobar; Mike Baiocchi Journal: Health Serv Res Date: 2020-10-30 Impact factor: 3.402
Authors: Ambarish Pandey; Kershaw V Patel; Li Liang; Adam D DeVore; Roland Matsouaka; Deepak L Bhatt; Clyde W Yancy; Adrian F Hernandez; Paul A Heidenreich; James A de Lemos; Gregg C Fonarow Journal: JAMA Cardiol Date: 2018-06-01 Impact factor: 14.676
Authors: Scott L Hummel; Wahida Karmally; Brenda W Gillespie; Stephen Helmke; Sergio Teruya; Joanna Wells; Erika Trumble; Omar Jimenez; Cara Marolt; Jeffrey D Wessler; Maria L Cornellier; Mathew S Maurer Journal: Circ Heart Fail Date: 2018-08 Impact factor: 8.790
Authors: Rishi K Wadhera; Karen E Joynt Maddox; Nihar R Desai; Bruce E Landon; Muthiah Vaduganathan Md; Lauren G Gilstrap; Changyu Shen; Robert W Yeh Journal: Ann Intern Med Date: 2020-10-13 Impact factor: 25.391